Senior Director, Global Market Access

Immunome, Inc.•Bothell, WA

2d•$236,650 - $320,791

About The Position

Immunome is seeking a highly experienced and strategic Senior Director, Global Market Access, to lead the development and execution of global market access strategies across our oncology portfolio. The individual will play a critical role in ensuring launch readiness globally, with particular emphasis on Europe, by aligning regulatory, pricing, and reimbursement pathways to support successful launch of varegacestat in countries outside of the US. This role will also be responsible for proactively integrating payer and HTA requirements into clinical development, evidence generation, and lifecycle planning for Immunome’s pipeline assets, to enable timely patient access and reimbursement across key markets. The successful candidate will bring deep expertise in global pricing and reimbursement, HTA engagement, and value dossier development, with a proven track record of successfully navigating HTA submissions and delivering reimbursement outcomes. This includes demonstrated experience leading market access strategy and execution for global launches, particularly across major EU markets (e.g., Germany, France, Italy, Spain, and the UK), including AMNOG processes, joint clinical assessments under the evolving EU HTA Regulation, and national pricing and negotiation frameworks. The role requires close collaboration with Regulatory, Clinical, Commercial, and regional affiliates to ensure evidence packages, value narratives, and pricing strategies are optimized for diverse global payer environments. This position offers a highly visible leadership opportunity to shape Immunome’s access strategy from early development through launch and beyond.

Requirements

Advanced degree (PharmD, PhD, MD, MSc, MPH, MBA) in life sciences, health economics, public health, pharmacy, or a related field; bachelor’s degree with equivalent experience considered.
12+ years experience in global market access, pricing, HTA, and reimbursement within biotech/pharma, including oncology or rare disease launch experience.
Demonstrated track record leading successful HTA submissions and achieving favorable reimbursement outcomes across multiple geographies (e.g., EU5/UK, Canada, Australia, etc.).
Proven experience obtaining and leveraging early scientific advice from global HTA bodies and payers to shape clinical development and evidence generation strategies.
Strong understanding of HEOR principles, cost-effectiveness and budget impact modeling, value communication, and evidence synthesis.
Experience leading cross-functional teams (Clinical Development, HEOR, Regulatory, Medical Affairs, Commercial, Finance) and managing multiple programs in a fast-paced environment.
30% travel.
Deep knowledge of global pricing and reimbursement landscapes and HTA requirements (e.g., NICE, G-BA/AMNOG, HAS, AIFA, SMC, CADTH, PBAC).
Ability to translate payer and HTA insights into actionable development strategy recommendations for endpoints, comparators, trial design, and evidence generation.
Expertise in global value story and value dossier development, including local adaptation; strong writing and content review capabilities.
Strong strategic thinking and program/project management skills, with the ability to prioritize across competing timelines and stakeholders.
Excellent communication and influencing skills, including experience presenting to executive leadership and facilitating decision making.
Proven vendor management and budgeting skills; ability to drive high-quality deliverables through external partners.
High learning agility and comfort operating across early-stage and late-stage development in a dynamic biotech environment.
Strong collaborative mindset and commitment to patient-centered access and compliant, ethical conduct.

Nice To Haves

Experience with EU HTA Joint Clinical Assessment (JCA) and/or Joint Scientific Consultation (JSC) processes preferred (nice to have).

Responsibilities

Develop and lead global market access, pricing, and reimbursement strategy across major markets for Immunome’s oncology portfolio, aligned with the target product profile (TPP) and commercial objectives.
Build and continuously refine the global payer value proposition, value messaging, and evidence needs (clinical, economic, and patient-relevant outcomes) to support reimbursement and uptake.
Provide strategic guidance on access risks, opportunities, and competitor dynamics; translate evolving HTA and payer expectations into actionable development and lifecycle recommendations.
Lead global access evidence planning and value dossier development, ensuring a consistent value story across regions and readiness for launch.
Obtain early scientific advice from HTA bodies and payers across geographies (e.g., NICE, G-BA, HAS, CADTH, PBAC and other key agencies) and advocate for incorporation of feedback into clinical development and evidence generation plans.
Partner with HEOR, Clinical Development, Biostatistics, Regulatory, Medical Affairs, and Commercial teams to drive integrated plans for endpoints, comparators, PROs, real-world evidence, and economic modeling.
Identify, qualify, and manage global market access vendors and consultants (e.g., HEOR modelers, dossier writers, policy advisors) to deliver high-quality outputs on time and within budget.
Maintain oversight of external partners supporting payer research, advisory boards, and submission execution, ensuring adherence to Immunome’s standards and regional requirements.
Lead development, review, and submission of global and regional HTA dossiers (e.g., NICE, SMC, G-BA/AMNOG, HAS, AIFA, CADTH, PBAC, ICER) and manage responses to HTA questions through appraisal and negotiation.
Drive strategy and content alignment for European joint assessments under the EU HTA framework, including participation in Joint Clinical Assessment (JCA) and Joint Scientific Consultation (JSC) activities where applicable (preferred; nice to have).
Ensure access deliverables are consistent with the regulatory label, clinical data package, and publication strategy; collaborate with Regulatory and Medical Writing on relevant evidence summaries and modules.
Serve as the market access lead on cross-functional program and asset teams, influencing decisions from early development through launch.
Communicate payer/HTA requirements and recommendations clearly to senior leadership and stakeholders; build alignment and accountability around access-critical activities.
Mentor and develop team members and foster a culture of collaboration, scientific rigor, and patient-centered decision making.